References
- Venook AP, Enders Klein C, Fleming G, et al. A phase I and farmocokinetic study of irinotecan in patients with hepat-ic and renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003; 14: 1783-1790.
- Shimida Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative in metastatic col-orectal cancer. J Clin Oncol 1993; 11: 909–913.
- Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer. N Eng J Med 2000; 343: 905–914.
- Karaoglu A, Yalgn S, Tekuzman G, et al. Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil- based chemotherapy: efficacy and prognostic factors. Tumori 2003; 89: 141–145.
- Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportif care versus sup-portif care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–1418.
- Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluo-rouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–1047.
- Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of on independent panel. J Clin Oncol 2001; 19: 3801–3807.
- Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with colorectal carcinoma. J Clin Oncol 1997; 15: 251–260.
- Stemmler J, Weise A, Hacker U, Heinemann V, Schalhorn A. Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to choronic renal fail-ure. Oncologie 2002; 25: 60–63.
- Johnson SW, O'dwyer PJ. Cisplatin and its analogues. In DeVita VT, Hellman S, Rosenberg SA (Eds). Cancer Principles and Practice of Oncology, 7th Edition, Lippincott Williams and Wilkins, Philadelphia, 2005: 344-356.